Revolution Medicines reported a transformational third quarter 2026, recording $197.6 million in net product revenue from the initial U.S. launch of RASONQUE (daraxonrasib). The results significantly exceeded top-line estimates and delivered a narrower-than-anticipated net loss, despite a substantial ramp-up in clinical development spending to support late-stage trials.
Key Highlights
- RASONQUE generated $197.6 million in net product revenue during its first five weeks post-FDA approval, serving over 5,000 unique patients in the U.S.
- Research and development expenses surged to $417.1 million, driven by higher clinical trial and manufacturing costs for the company's expanding Phase 3 portfolio.
- The company maintains a robust liquidity position with $3.7 billion in cash and marketable securities, excluding an additional $250 million debt tranche received in October.